Diabetogenic effect of steroids

[ corrected ] Controversy exists regarding the use of CCBs, particularly the dihydropyridines (., amlodipine [Norvasc], nifedipine [Procardia]) in treating hypertension in patients with diabetes. Five studies 21 – 25 have evaluated cardiovascular outcomes in patients with hypertension and diabetes who were treated with dihydropyridine CCBs. Both the Appropriate Blood Pressure Control in Diabetes (ABCD) 21 trial and the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) 22 demonstrated no significant reduction in cardiovascular events with a dihydropyridine CCB compared with an ACE inhibitor. [Reference 22 —Evidence level B, uncontrolled study]

Diabetogenic effect of steroids

diabetogenic effect of steroids

Media:

diabetogenic effect of steroidsdiabetogenic effect of steroidsdiabetogenic effect of steroidsdiabetogenic effect of steroidsdiabetogenic effect of steroids